Loading...
Please wait, while we are loading the content...
United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
| Content Provider | Europe PMC |
|---|---|
| Author | Tarantelli, Chiara Bertoni, Francesco |
| Abstract | SummaryPolatuzumab vedotin is antibody‐drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B‐cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC.Commentary on: Kawasaki et al. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma. Br J Haematol 2022;199:245‐255. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9804191&blobtype=pdf |
| Page Count | 2 |
| ISSN | 00071048 |
| Journal | British Journal of Haematology [Br J Haematol] |
| Volume Number | 199 |
| DOI | 10.1111/bjh.18384 |
| PubMed Central reference number | PMC9804191 |
| Issue Number | 2 |
| PubMed reference number | 35917107 |
| e-ISSN | 13652141 |
| Language | English |
| Publisher | John Wiley and Sons Inc. |
| Publisher Date | 2022-08-02 |
| Publisher Place | Hoboken |
| Access Restriction | Open |
| Rights License | This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. |
| Subject Keyword | antibody‐drug conjugate lymphoma MMAE polatuzumab vedotin resistance rituximab |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hematology |